NCT03595059 2025-12-10
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Phase 1 Completed
AbbVie
AstraZeneca
Takeda
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Samsung Medical Center
GlaxoSmithKline